Tell Gilead to Stop Withholding a Cure for Hepatitis C
AIDS Healthcare Foundation is supporting the HCV Coalition for the Cure in its
call for Gilead to stop the greed and help people affected by Hepatitis C
Gilead Science's GS-7977 (sofosbuvir), when combined with Bristol-Myers Squibb's (BMS) drug daclatasvir, achieved a 100% cure rate for Hepatitis C in a recent clinical trial. However, Gilead is refusing to co-develop the drug with BMS in order to cash in by developing its own treatment. To date, studies have shown Gilead’s version of this treatment to be less effective and potentially less safe for patients.
"The unfettered greed that drives the lack of cooperation between pharmaceutical giants Gilead and Bristol-Myers Squibbs comes at the unacceptably high price of the health and wellbeing of Hepatitis C patients," said AHF President Michael Weinstein. "The withholding of effective treatment for patients suffering from this illness to instead boost shareholder returns has gone on for too long, and as the new year begins, so must this travesty end."
Learn more about the ongoing lag in collaboration between Gilead and BMS, as featured earlier this year in the New York Times: